officialstreetpreachers Subscribe
Published: August 20, 2021

Big pharma eyes next childhood vaccine cash cow — mRNA vaccines for RSV

By The Editor

Fri Aug 20, 2021 – 6:51 am EDTFri Aug 20, 2021 – 5:58 am EDT

LifeSiteNews has produced an extensive COVID-19 vaccines resources page. View it here. 

(Children’s Health Defense) – Over the decades since childhood vaccines began rolling out on a widespread scale, pediatric vaccine injuries have left many parents regretful for forgetting or ignoring a basic history lesson.

That lesson, in the words of Harvard medical historian David Jones, is that “when it comes to vaccines and immunization … there always has been a risk and there always will be a risk.”

Sixty-five years ago, families learned about the risks of medical experimentation the hard way when they allowed researchers to use their infants as test subjects for a vaccine against a newly discovered illness dubbed “respiratory syncytial virus” (RSV), a common-cold-like illness now considered to affect “virtually all children,” mostly uneventfully, by age two.

The disastrous RSV vaccine led to the death of two infants and to hospitalization for the majority of other young clinical trial participants.

Since that time, vexed researchers have continued to deploy “trial-and-error approaches.” But they admit the “road to an effective RSV vaccine is paved with challenges,” in large part because of the tricky problem of “vaccine-associated disease exacerbation” — a problem that has

The remainder of this article is available in its entirety at LifeSite News

The views expressed in this news alert by the author do not directly represent that of The Official Street Preachers or its editors


Share this Article

Download the Mobile App.
Exit mobile version